Developer docs
API playgroundTry for free, no card

Search company profiles

Dynavax Technologies

Full company profile

uuid0002jya

Namestring
Dynavax Technologies
Legal namestring
Dynavax Technologies Corporation
Websiteurl
dynavax.com
Company typeenum
Public
Founded yearint
1997
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hepatitis B vaccine, vaccine adjuvant technology, toll-like receptor agonist, infectious disease prevention, biopharmaceutical vaccines
Industry3 codes
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1HEPLISAV-B Vaccine Sales
TypeOne Time License
Description

Dynavax generates revenue primarily from sales of its FDA-approved hepatitis B vaccine HEPLISAV-B. The vaccine generated $268 million in 2024 sales, representing 26% year-over-year growth. Q3 2025 revenue was $94.9 million, up 18% year-over-year.

prnewswire.com
2Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Dynavax receives upfront payments, equity investments, and potential milestone payments from partnerships. The Vaxart partnership provided $25 million upfront plus $5 million equity investment with up to $700 million in total potential milestones, royalties, and fees.

finance.yahoo.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1HEPLISAV-B
Description

FDA-approved adult hepatitis B vaccine using CpG 1018 adjuvant technology.

dynavax.com
+1 more record
Core offering1 text field

Dynavax develops, manufactures, and commercializes novel vaccines against infectious diseases built around its proprietary CpG 1018 toll-like receptor 9 (TLR9) agonist adjuvant. Its flagship commercial product is HEPLISAV-B, an FDA-approved two-dose adult hepatitis B vaccine administered over one month, with a pipeline including the Z-1018 investigational shingles vaccine candidate in Phase 1/2 trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 26% year-over-year revenue growth for HEPLISAV-B in 2024, reaching $268 million in sales.
+1 more record
Product overview1 text field

Dynavax Technologies is a commercial-stage biopharmaceutical company that develops and commercializes novel vaccines to protect against infectious diseases. The company's portfolio centers on its proprietary CpG 1018® adjuvant technology, which is contained in its FDA-approved hepatitis B vaccine HEPLISAV-B® (launched Q1 2018 in the US, Q2 2022 in the EU). The pipeline includes Z-1018, a shingles vaccine candidate in Phase 1/2 trials, and various other vaccine programs. Dynavax was acquired by Sanofi in February 2026.

Product and service2 records
1HEPLISAV-B
CategoryVaccines
Description

HEPLISAV-B is an FDA-approved adult hepatitis B vaccine that uses Dynavax's proprietary CpG 1018 adjuvant and is delivered as a two-dose regimen (one month apart) for adults 18 years and older, including those with chronic kidney disease and type 2 diabetes mellitus.

2CpG 1018 Adjuvant
CategoryVaccine adjuvant / licensing platform
Description

CpG 1018 is Dynavax's proprietary toll-like receptor 9 (TLR9) agonist adjuvant contained in HEPLISAV-B. It is licensed to biopharmaceutical partners for use in their vaccine candidates in exchange for upfront payments, equity investments, milestone payments, royalties, and fees.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2025-12-24
Description

Sanofi completed its acquisition of Dynavax Technologies on February 10, 2026, for approximately $2.2 billion ($15.50 per share). The acquisition brings Sanofi's adult hepatitis B vaccine HEPLISAV-B and the Z-1018 shingles vaccine candidate (in Phase 1/2). Dynavax became an indirect wholly owned subsidiary of Sanofi, with its shares delisted from Nasdaq.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Dynavax entered an exclusive worldwide license and collaboration agreement with Vaxart in November 2025 to develop and commercialize Vaxart's oral COVID-19 vaccine candidate. Dynavax paid $25 million upfront plus a $5 million equity investment, with up to $700 million in potential milestones, royalties, and fees. Vaxart continues leading development through Phase 2b, after which Dynavax may assume late-stage development and commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large vaccine and biologics manufacturer with a portfolio that historically included Recombivax HB for hepatitis B. Highly comparable in commercial-stage vaccine distribution to healthcare providers, biopharmaceutical R&D scale, and infectious disease focus.

TypeDirect peer
Description

Commercial-stage vaccine company with an mRNA-based platform, originally commercialized through its COVID-19 partnership with Pfizer and now expanding into infectious disease and oncology vaccines. Comparable as a platform vaccine company leveraging novel immunological technology to develop infectious disease products.

TypeDirect peer
Description

Vaccine developer using proprietary Matrix-M adjuvant technology to enhance immune responses in protein-based vaccines. Comparable because of a similarly adjuvant-driven platform approach, focus on infectious disease vaccines, and commercial-stage status with established supply and distribution partnerships.

4Valneva
TypeDirect peer
Description

Specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases, including chikungunya, Lyme disease, and travel vaccines. Comparable as a commercial-stage vaccine developer with a focused infectious disease pipeline targeting adult and travel populations.

TypeBroad incumbent
Description

Global biopharmaceutical company with a large vaccines franchise, including Shingrix (the direct competitor to Dynavax's Z-1018 shingles candidate) and prior hepatitis B vaccines. Comparable because of overlapping vaccine categories, immune-adjuvant research, and primary-care provider relationships that drive adult vaccine adoption.

TypeEmerging player
Description

Clinical-stage vaccine developer using a DNA-based platform to target infectious diseases and cancer. Comparable as a smaller platform-vaccine company focused on novel immune-activation approaches for infectious disease indications.

TypeDirect peer
Description

Biopharmaceutical company developing vaccines and therapeutics for infectious diseases and public health threats, with a portfolio that includes travel and routine vaccines. Comparable as a mid-cap commercial vaccine company with comparable R&D and manufacturing capabilities targeting infectious disease prevention.

8Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi's vaccines division and now the parent organization of Dynavax following the February 2026 acquisition. Highly comparable in adult vaccine commercialization, hepatitis B franchise, and adjuvant technology development across the broader Sanofi vaccine portfolio.

TypeDirect peer
Description

Vaccine developer with approved hepatitis B vaccine (PreHevbrio/Sci-B-Vac) targeting adult and dialysis populations, directly overlapping with HEPLISAV-B's positioning. Comparable as a hepatitis B vaccine competitor with a similar adult-vaccination commercial focus.

TypeDirect peer
Description

mRNA vaccine platform company with approved COVID-19 and RSV vaccines and a broad infectious disease pipeline. Comparable as a commercial-stage vaccine developer with platform-based technology, focused on infectious disease prevention in adult populations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dynavax Technologies

Vaccinesdynavax.com

Dynavax Technologies firmographics

Firmographics
Name
Dynavax Technologies
Legal name
Dynavax Technologies Corporation
Website
https://dynavax.com
Company type
Public
Founded year
1997
Operating status
Acquired
Headcount range
101–250 employees
Ownership category
akta.pro rank

Dynavax Technologies industry classification

Industry
Product category
Vaccines
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)

Keywords

  • Hepatitis B vaccine
  • Vaccine adjuvant technology
  • Toll-like receptor agonist
  • Infectious disease prevention
  • Biopharmaceutical vaccines

Where Dynavax Technologies is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Dynavax Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. HEPLISAV-B Vaccine Sales: Dynavax generates revenue primarily from sales of its FDA-approved hepatitis B vaccine HEPLISAV-B. The vaccine generated $268 million in 2024 sales, representing 26% year-over-year growth. Q3 2025 revenue was $94.9 million, up 18% year-over-year.
  2. Partnership and Licensing Revenue: Dynavax receives upfront payments, equity investments, and potential milestone payments from partnerships. The Vaxart partnership provided $25 million upfront plus $5 million equity investment with up to $700 million in total potential milestones, royalties, and fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Dynavax Technologies product offering

Product offering

Core offering

Dynavax develops, manufactures, and commercializes novel vaccines against infectious diseases built around its proprietary CpG 1018 toll-like receptor 9 (TLR9) agonist adjuvant. Its flagship commercial product is HEPLISAV-B, an FDA-approved two-dose adult hepatitis B vaccine administered over one month, with a pipeline including the Z-1018 investigational shingles vaccine candidate in Phase 1/2 trials.

Product overview

Dynavax Technologies is a commercial-stage biopharmaceutical company that develops and commercializes novel vaccines to protect against infectious diseases. The company's portfolio centers on its proprietary CpG 1018® adjuvant technology, which is contained in its FDA-approved hepatitis B vaccine HEPLISAV-B® (launched Q1 2018 in the US, Q2 2022 in the EU). The pipeline includes Z-1018, a shingles vaccine candidate in Phase 1/2 trials, and various other vaccine programs. Dynavax was acquired by Sanofi in February 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • HEPLISAV-B: FDA-approved adult hepatitis B vaccine using CpG 1018 adjuvant technology.
  • CpG 1018

Products and services

  • HEPLISAV-B HEPLISAV-B is an FDA-approved adult hepatitis B vaccine that uses Dynavax's proprietary CpG 1018 adjuvant and is delivered as a two-dose regimen (one month apart) for adults 18 years and older, including those with chronic kidney disease and type 2 diabetes mellitus.
  • CpG 1018 Adjuvant CpG 1018 is Dynavax's proprietary toll-like receptor 9 (TLR9) agonist adjuvant contained in HEPLISAV-B. It is licensed to biopharmaceutical partners for use in their vaccine candidates in exchange for upfront payments, equity investments, milestone payments, royalties, and fees.

Quantifiable outcome

  • 26% year-over-year revenue growth for HEPLISAV-B in 2024, reaching $268 million in sales.
  • +1 more outcomes

Companies that use Dynavax Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Dynavax Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Dynavax Technologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SanoficoreOthers · 24 December 2025Sanofi completed its acquisition of Dynavax Technologies on February 10, 2026, for approximately $2.2 billion ($15.50 per share). The acquisition brings Sanofi's adult hepatitis B vaccine HEPLISAV-B and the Z-1018 shingles vaccine candidate (in Phase 1/2). Dynavax became an indirect wholly owned subsidiary of Sanofi, with its shares delisted from Nasdaq.
  • VaxartcoreStrategic or Co-development Partner · 5 November 2025Dynavax entered an exclusive worldwide license and collaboration agreement with Vaxart in November 2025 to develop and commercialize Vaxart's oral COVID-19 vaccine candidate. Dynavax paid $25 million upfront plus a $5 million equity investment, with up to $700 million in potential milestones, royalties, and fees. Vaxart continues leading development through Phase 2b, after which Dynavax may assume late-stage development and commercialization.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Dynavax Technologies competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Large vaccine and biologics manufacturer with a portfolio that historically included Recombivax HB for hepatitis B. Highly comparable in commercial-stage vaccine distribution to healthcare providers, biopharmaceutical R&D scale, and infectious disease focus.
  • GSK: Global biopharmaceutical company with a large vaccines franchise, including Shingrix (the direct competitor to Dynavax's Z-1018 shingles candidate) and prior hepatitis B vaccines. Comparable because of overlapping vaccine categories, immune-adjuvant research, and primary-care provider relationships that drive adult vaccine adoption.
  • Sanofi Pasteur: Sanofi's vaccines division and now the parent organization of Dynavax following the February 2026 acquisition. Highly comparable in adult vaccine commercialization, hepatitis B franchise, and adjuvant technology development across the broader Sanofi vaccine portfolio.

Direct peers

  • BioNTech: Commercial-stage vaccine company with an mRNA-based platform, originally commercialized through its COVID-19 partnership with Pfizer and now expanding into infectious disease and oncology vaccines. Comparable as a platform vaccine company leveraging novel immunological technology to develop infectious disease products.
  • Novavax: Vaccine developer using proprietary Matrix-M adjuvant technology to enhance immune responses in protein-based vaccines. Comparable because of a similarly adjuvant-driven platform approach, focus on infectious disease vaccines, and commercial-stage status with established supply and distribution partnerships.
  • Valneva: Specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases, including chikungunya, Lyme disease, and travel vaccines. Comparable as a commercial-stage vaccine developer with a focused infectious disease pipeline targeting adult and travel populations.
  • Emergent BioSolutions: Biopharmaceutical company developing vaccines and therapeutics for infectious diseases and public health threats, with a portfolio that includes travel and routine vaccines. Comparable as a mid-cap commercial vaccine company with comparable R&D and manufacturing capabilities targeting infectious disease prevention.
  • VBI Vaccines: Vaccine developer with approved hepatitis B vaccine (PreHevbrio/Sci-B-Vac) targeting adult and dialysis populations, directly overlapping with HEPLISAV-B's positioning. Comparable as a hepatitis B vaccine competitor with a similar adult-vaccination commercial focus.
  • Moderna: mRNA vaccine platform company with approved COVID-19 and RSV vaccines and a broad infectious disease pipeline. Comparable as a commercial-stage vaccine developer with platform-based technology, focused on infectious disease prevention in adult populations.

Emerging players

  • Inovio Pharmaceuticals: Clinical-stage vaccine developer using a DNA-based platform to target infectious diseases and cancer. Comparable as a smaller platform-vaccine company focused on novel immune-activation approaches for infectious disease indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Dynavax Technologies social profiles

Digital presence

Dynavax Technologies compliance and trust

Trust signal

Compliance6 records

Dynavax Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dynavax Technologies leadership team

Management profile

Number of profiles

Profiles6 records

Dynavax Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Dynavax Technologies funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dynavax Technologies M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dynavax Technologies

What does Dynavax Technologies do?

Dynavax develops, manufactures, and commercializes novel vaccines against infectious diseases built around its proprietary CpG 1018 toll-like receptor 9 (TLR9) agonist adjuvant. Its flagship commercial product is HEPLISAV-B, an FDA-approved two-dose adult hepatitis B vaccine administered over one month, with a pipeline including the Z-1018 investigational shingles vaccine candidate in Phase 1/2 trials.

Is Dynavax Technologies a public or private company?

Dynavax Technologies is a public company. It is classified as corporate owned and is currently acquired.

When was Dynavax Technologies founded?

Dynavax Technologies was founded in 1997. It employs 101 to 250 people.

Where is Dynavax Technologies based?

Dynavax Technologies is headquartered in Emeryville, United States, in the North America region.

How does Dynavax Technologies make money?

Two revenue lines are on record. HEPLISAV-B Vaccine Sales are the primary driver. The others are partnership and Licensing Revenue.

Who are Dynavax Technologies's main competitors?

Broad incumbents on record are Merck & Co., GSK and Sanofi Pasteur. Direct peers are BioNTech, Novavax, Valneva, Emergent BioSolutions, VBI Vaccines and Moderna. Inovio Pharmaceuticals is listed as an emerging player.

Does Dynavax Technologies have an API?

No public API is recorded for Dynavax Technologies.

What industry is Dynavax Technologies in?

Dynavax Technologies's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAIAEAI, Vaccine Adjuvants & Formulation Systems. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestVXRT: The Q2 Revenue Decline Is Accounting Noise — the $675 Million Optionality Is What the Market Is IgnoringVaxart reported Q2 revenue of $27.2 million, a 31% decline year-over-year, driven by the winding down of BARDA contract billing milestones rather than business deterioration. The company holds $675 million in contingent milestones from Dynavax Technologies and a separate $700 million milestone path with Sanofi tied to its oral COVID-19 vaccine program, while currently trading at a $130 million market cap. The Phase 2b efficacy readout expected in the first half of 2027 represents a binary catalyst that the market is currently not pricing in, with clean safety data from a 400-person sentinel cohort already reported in July 2026.BioSpaceVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYVaxart mailed a letter to shareholders urging them to vote "FOR" all six of its director nominees on the white proxy card ahead of its July 16, 2026 annual meeting. The company argues the nominees have relevant biotechnology and public company leadership experience, while dissident nominees lack such credentials. It also highlights ongoing clinical trials and a $25 million share purchase agreement.Stock TitanARS Pharma taps Donn Casale as presidentARS Pharmaceuticals, Inc. appointed Donn Casale as President effective June 1, 2026, with CEO Richard Lowenthal continuing to lead the company. Casale, a 25-year biopharmaceutical commercial veteran previously Chief Commercial Officer at Dynavax Technologies, will oversee global commercial operations and growth infrastructure as ARS Pharma expands its neffy® epinephrine nasal spray business and enters chronic spontaneous urticaria. The appointment reflects the company's next phase of commercial and organizational growth, with Casale's track record of scaling HEPLISAV-B to over $300 million in annualized revenue cited as key to driving neffy adoption.pharmaphorumSanofi welcomes incoming CEO with sales liftSanofi's new CEO Belén Garijo will start her tenure with a 13.6% revenue rise to over €10.5 billion in Q1 2026, driven by Dupixent and hepatitis B vaccines. The company expects sales growth of high single digits and business EPS to outpace sales. Garijo is due to take office on April 29.EIN PresswireShingles Treatment Market Growth Overview, Facts & Figures, Segmentation, Future Trends and Historical Analysis By 2033The global shingles treatment market is projected to grow from USD 136.15 billion in 2026 to USD 260.29 billion by 2033, a CAGR of 9.7%. Vaccines hold a 74.3% market share in 2025, with North America leading at 39.3% and Asia Pacific expected to become a lucrative market.GlobeNewswireHeplisav-B Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FA market research report projects growth in the Heplisav-B adult hepatitis B vaccine market, driven by low compliance with three-dose vaccines and rising hepatitis B prevalence among adults. Dynavax Technologies Corporation received approval for Heplisav-B in Great Britain in 2023, and the vaccine offers a convenient two-dose schedule using a TLR 9 agonist adjuvant for enhanced seroprotection. North America currently leads the market while Asia-Pacific is expected to see rapid growth, with trends favoring two-dose vaccines and expanded adult immunization mandates.Investing.comOnespaWorld stock hits all-time high at 23.5 USD By Investing.comOneSpaWorld Holdings Ltd (OSW) stock reached an all-time high of $23.50 on the NASDAQ, reflecting strong investor confidence supported by a perfect Piotroski Score of 9 and a "GREAT" financial health rating. The company announced preliminary fiscal year 2025 revenue expectations of $958.5–963.5 million, representing approximately 7% growth from fiscal 2024, while also projecting 2026 revenues of up to $1.03 billion. Additionally, OneSpaWorld is set to join the S&P SmallCap 600 index prior to market opening on February 10, replacing Dynavax Technologies, with Stifel maintaining a Buy rating despite lowering its price target from $27 to $26.Investing.comSanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting By Investing.comSanofi has completed its acquisition of Dynavax Technologies, with the transaction finalized after a tender offer where approximately 73.92% of Dynavax's outstanding shares were tendered at $15.50 per share in cash. Following the merger, Dynavax's shares were delisted from the Nasdaq Global Select Market, and the company plans to file for deregistration with the SEC. The transaction was valued at approximately $2.2 billion, representing a 39% premium over Dynavax's closing share price on December 23, 2025.Investing.comSanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting By Investing.comSanofi completed its acquisition of Dynavax Technologies on Tuesday, finalizing the transaction after a tender offer that expired at one minute past 11:59 p.m. Eastern Time on Monday, with 73.92% of Dynavax's outstanding shares tendered at $15.50 per share in cash. The deal, valued at approximately $2.2 billion, represented a 39% premium over Dynavax's closing share price on December 23, 2025, and has resulted in Dynavl being delisted from the Nasdaq Global Select Market with plans to deregister with the SEC. Following the merger, Dynavax's board of directors resigned and Sanofi appointed new leadership to the company, which is now an indirect wholly owned subsidiary of Sanofi.